Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design.
Gregory Russell Pond
No relevant relationships to disclose
Joaquim Bellmunt
Research Funding - Pierre Fabre Medicament
Ronan Fougeray
Employment or Leadership Position - Pierre Fabre Medicament
Toni K. Choueiri
Research Funding - AstraZeneca
Angela Q. Qu
Research Funding - AstraZeneca
Yacine Salhi
Employment or Leadership Position - Pierre Fabre Medicament
Research Funding - Bristol-Myers Squibb; Lilly
Guenter Niegisch
Research Funding - Bristol-Myers Squibb; Lilly
Peter Albers
Research Funding - Bristol-Myers Squibb; Lilly
Giuseppe Di Lorenzo
No relevant relationships to disclose
Matt D. Galsky
No relevant relationships to disclose
Andrea Necchi
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Guru Sonpavde
No relevant relationships to disclose